NCT02452866View on ClinicalTrials.gov

Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219

PHASE3CompletedINTERVENTIONAL
Enrollment

325

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Bacterial Vaginosis
Interventions
DRUG

SYM-1219

Administered with 4 ounces of unsweetened applesauce, and 8 ounces of water

Trial Locations (40)

19107

Philadelphia

19114

Philadelphia

21224

Baltimore

23456

Virginia Beach

23507

Norfolk

27103

Winston-Salem

28562

New Bern

29572

Myrtle Beach

30075

Roswell

30312

Atlanta

31904

Columbus

33161

North Miami

33186

Miami

33324

Plantation

33414

Wellington

33759

Clearwater

34748

Leesburg

35294

Birmingham

38305

Jackson

43213

Columbus

43231

Columbus

48604

Saginaw

49009

Kalamazoo

49503

Grand Rapids

66218

Shawnee Mission

72401

Jonesboro

75231

Dallas

77054

Houston

78229

San Antonio

78414

Corpus Christi

80209

Denver

80907

Colorado Springs

85018

Phoenix

91942

La Mesa

92108

San Diego

98104

Seattle

98105

Seattle

06340

Groton

02720

Fall River

08536

Plainsboro

Sponsors
All Listed Sponsors
lead

Symbiomix Therapeutics

INDUSTRY